SI2152701T1 - Spojine fenil amino pirimidina in njihova uporaba - Google Patents
Spojine fenil amino pirimidina in njihova uporabaInfo
- Publication number
- SI2152701T1 SI2152701T1 SI200831536T SI200831536T SI2152701T1 SI 2152701 T1 SI2152701 T1 SI 2152701T1 SI 200831536 T SI200831536 T SI 200831536T SI 200831536 T SI200831536 T SI 200831536T SI 2152701 T1 SI2152701 T1 SI 2152701T1
- Authority
- SI
- Slovenia
- Prior art keywords
- phenyl amino
- pyrimidine compounds
- amino pyrimidine
- compounds
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89426407P | 2007-03-12 | 2007-03-12 | |
US1625207P | 2007-12-21 | 2007-12-21 | |
EP08714386.3A EP2152701B1 (en) | 2007-03-12 | 2008-03-12 | Phenyl amino pyrimidine compounds and uses thereof |
PCT/AU2008/000339 WO2008109943A1 (en) | 2007-03-12 | 2008-03-12 | Phenyl amino pyrimidine compounds and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2152701T1 true SI2152701T1 (sl) | 2016-03-31 |
Family
ID=39758909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200831536T SI2152701T1 (sl) | 2007-03-12 | 2008-03-12 | Spojine fenil amino pirimidina in njihova uporaba |
Country Status (22)
Country | Link |
---|---|
US (5) | US8486941B2 (sl) |
EP (2) | EP3023422A1 (sl) |
JP (5) | JP2010520892A (sl) |
KR (3) | KR101566840B1 (sl) |
CN (2) | CN101861313B (sl) |
AU (1) | AU2008226327B2 (sl) |
BR (2) | BR122020010759B1 (sl) |
CA (1) | CA2702650C (sl) |
CY (1) | CY1117180T1 (sl) |
DK (1) | DK2152701T3 (sl) |
ES (1) | ES2557930T3 (sl) |
HK (1) | HK1149749A1 (sl) |
HR (1) | HRP20151386T1 (sl) |
HU (1) | HUE029188T2 (sl) |
MX (1) | MX2009009792A (sl) |
PL (1) | PL2152701T3 (sl) |
PT (1) | PT2152701E (sl) |
RS (1) | RS54533B1 (sl) |
RU (1) | RU2498983C2 (sl) |
SI (1) | SI2152701T1 (sl) |
WO (1) | WO2008109943A1 (sl) |
ZA (1) | ZA200906848B (sl) |
Families Citing this family (205)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2152701T3 (pl) | 2007-03-12 | 2016-10-31 | Związki fenyloaminopirymidyny i ich zastosowania | |
US8530480B2 (en) | 2007-09-04 | 2013-09-10 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
WO2009103032A1 (en) * | 2008-02-15 | 2009-08-20 | Rigel Pharmaceuticals, Inc. | Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases |
CA2713716A1 (en) * | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
CN102791697A (zh) * | 2009-10-12 | 2012-11-21 | 瑞科西有限公司 | 作为TBKL和/或IKKε抑制剂的氨基-嘧啶化合物 |
GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
JP2014500254A (ja) | 2010-11-09 | 2014-01-09 | セルゾーム リミティッド | Tyk2阻害剤としてのピリジン化合物およびそのアザ類似体 |
MX2013006261A (es) * | 2010-12-03 | 2013-10-01 | Ym Biosciences Australia Pty | Tratamiento de condiciones mediadas por jak2. |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
JP5947818B2 (ja) * | 2011-03-02 | 2016-07-06 | リード ディスカバリー センター ゲーエムベーハー | 薬学的活性化二置換ピリジン誘導体 |
ES2613103T3 (es) | 2011-04-19 | 2017-05-22 | Bayer Intellectual Property Gmbh | 4-Aril-n-fenil-1,3,5-triacin-2-aminas sustituidas |
MX2013012785A (es) * | 2011-05-02 | 2014-05-28 | Ym Biosciences Australia Pty | Tratamiento del mieloma multiple. |
TWI555737B (zh) | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
DE102011112978A1 (de) | 2011-09-09 | 2013-03-14 | Merck Patent Gmbh | Benzonitrilderivate |
EP2755956B1 (en) | 2011-09-16 | 2016-05-18 | Bayer Intellectual Property GmbH | 2,4-disubstituted 5-fluoro-pyrimidines as selective cdk9 inhibtors |
ES2588102T3 (es) | 2011-09-16 | 2016-10-28 | Bayer Intellectual Property Gmbh | Derivados de 5-fluoro-pirimidina disustituidos que contienen un grupo sulfoximina |
CN103102359B (zh) * | 2011-11-15 | 2016-11-09 | 江苏先声药业有限公司 | 嘧啶类化合物及其应用 |
IL289834B1 (en) | 2012-06-13 | 2024-03-01 | Incyte Holdings Corp | Conversion of tricyclic compounds as FGFR inhibitors |
US8809359B2 (en) * | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
CN104854091B (zh) | 2012-10-18 | 2018-04-03 | 拜耳药业股份公司 | 含砜基团的5‑氟‑n‑(吡啶‑2‑基)吡啶‑2‑胺衍生物 |
CA2888381A1 (en) | 2012-10-18 | 2014-04-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
WO2014075318A1 (zh) * | 2012-11-19 | 2014-05-22 | 江苏先声药业有限公司 | 嘧啶类化合物及其应用 |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
MX2015008829A (es) * | 2013-01-09 | 2016-04-25 | Concert Pharmaceuticals Inc | Momelotinib deuterado. |
CN103965114B (zh) * | 2013-01-28 | 2016-01-06 | 苏州泽璟生物制药有限公司 | 氘代的苯基氨基嘧啶化合物以及包含该化合物的药物组合物 |
SI2986610T1 (sl) | 2013-04-19 | 2018-04-30 | Incyte Holdings Corporation | Biciklični heterocikli kot inhibitorji FGFR |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
WO2015019365A1 (en) * | 2013-08-07 | 2015-02-12 | Cadila Healthcare Limited | N-cyanomethylamides as inhibitors of janus kinase |
AU2014354769A1 (en) * | 2013-11-26 | 2016-05-26 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
EP3080100B1 (en) * | 2013-12-11 | 2022-11-30 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
AU2015206194A1 (en) | 2014-01-20 | 2016-07-28 | Gilead Sciences, Inc. | Therapies for treating cancers |
ES2921874T3 (es) | 2014-02-28 | 2022-09-01 | Nimbus Lakshmi Inc | Inhibidores de TYK2 y usos de los mismos |
TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
TWI729644B (zh) | 2014-06-12 | 2021-06-01 | 美商西爾拉癌症醫學公司 | N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺 |
BR112016028814A2 (pt) | 2014-06-13 | 2017-08-22 | Gilead Sciences Inc | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? |
US11021467B2 (en) | 2014-06-13 | 2021-06-01 | Gilead Sciences, Inc. | Phosphatidylinositol 3-kinase inhibitors |
RS63364B1 (sr) | 2014-08-11 | 2022-07-29 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora |
US20170224819A1 (en) | 2014-08-11 | 2017-08-10 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor |
RS62713B1 (sr) | 2014-08-11 | 2022-01-31 | Acerta Pharma Bv | Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora |
CN117164657A (zh) | 2014-08-12 | 2023-12-05 | 莫纳什大学 | 定向淋巴的前药 |
CN104262263B (zh) * | 2014-08-29 | 2017-01-11 | 西安交通大学 | 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用 |
SG11201701724VA (en) | 2014-09-26 | 2017-04-27 | Gilead Sciences Inc | Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds |
ES2720525T3 (es) | 2014-10-16 | 2019-07-22 | Bayer Pharma AG | Derivados fluorados de benzofuranil-pirimidina que contienen un grupo sulfona |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
ES2751669T3 (es) | 2015-02-20 | 2020-04-01 | Incyte Corp | Heterociclos bicíclicos como inhibidores FGFR |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
TWI744225B (zh) | 2015-02-27 | 2021-11-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
JP2018509439A (ja) | 2015-03-24 | 2018-04-05 | バイエル ファーマ アクチエンゲゼルシャフト | 多発性骨髄腫を治療するための4−(4−フルオロ−2−メトキシフェニル)−n−{3−[(s−メチルスルホンイミドイル)メチル]フェニル}−1,3,5−トリアジン−2−アミンの使用 |
WO2016150903A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas |
WO2016150902A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers |
CN106316964B (zh) * | 2015-06-26 | 2019-06-25 | 苏州泽璟生物制药股份有限公司 | 苯基氨基嘧啶化合物或其盐的多晶型物 |
CN106316963B (zh) * | 2015-06-26 | 2021-06-08 | 苏州泽璟生物制药股份有限公司 | ***啉苯基氨基嘧啶化合物或其盐的多晶型物 |
WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
WO2017040757A1 (en) | 2015-09-02 | 2017-03-09 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
US11738087B2 (en) | 2015-09-08 | 2023-08-29 | Monash University | Lymph directing prodrugs |
WO2017044720A1 (en) | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
JP6847099B2 (ja) | 2015-09-29 | 2021-03-24 | バイエル ファーマ アクチエンゲゼルシャフト | 新規な大環状スルホンジイミン化合物 |
WO2017060167A1 (en) | 2015-10-08 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
SI3364958T1 (sl) | 2015-10-23 | 2023-05-31 | Navitor Pharmaceuticals, Inc. | Modulatorji interakcije sestrina in gator2 ter njihova uporaba |
EP3389664A4 (en) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
JP2019505498A (ja) | 2015-12-16 | 2019-02-28 | ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ | Nk細胞におけるサイトカイン誘導性sh2タンパク質の阻害 |
PL3426243T3 (pl) | 2016-03-09 | 2021-10-04 | Raze Therapeutics, Inc. | Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania |
ES2949357T3 (es) | 2016-03-09 | 2023-09-28 | Raze Therapeutics Inc | Inhibidores de 3-fosfoglicerato deshidrogenasa y usos de los mismos |
CN105837515B (zh) * | 2016-04-06 | 2018-08-03 | 中国药科大学 | 一种JAK抑制剂Momelotinib的制备方法 |
JP2019510785A (ja) | 2016-04-08 | 2019-04-18 | エックス4 ファーマシューティカルズ, インコーポレイテッド | 癌を処置する方法 |
JP6994767B2 (ja) | 2016-06-21 | 2022-01-14 | エックス4 ファーマシューティカルズ, インコーポレイテッド | Cxcr4阻害剤およびその使用 |
EP3808748A1 (en) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
WO2018031579A1 (en) | 2016-08-10 | 2018-02-15 | Gilead Sciences, Inc. | Momelotinib for treating of acvr1 -mediated diseases |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
WO2018057808A1 (en) | 2016-09-23 | 2018-03-29 | Gilead Sciences, Inc. | Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
AU2017342464B2 (en) | 2016-10-14 | 2021-09-16 | Takeda Pharmaceutical Company Limited | TYK2 inhibitors and uses thereof |
WO2018075937A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
EP3538091A4 (en) | 2016-11-08 | 2020-06-10 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF |
EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | EXOSOMES FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS |
US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
AR111233A1 (es) | 2017-03-08 | 2019-06-19 | Nimbus Lakshmi Inc | Inhibidores de tyk2, usos y métodos para la producción de los mismos |
EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
PL3601253T3 (pl) | 2017-03-28 | 2022-01-17 | Bayer Aktiengesellschaft | Nowe hamujące ptefb związki makrocykliczne |
EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
US11339144B2 (en) | 2017-04-10 | 2022-05-24 | Navitor Pharmaceuticals, Inc. | Heteroaryl Rheb inhibitors and uses thereof |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
JP7179015B2 (ja) | 2017-04-26 | 2022-11-28 | ナビター ファーマシューティカルズ, インコーポレイテッド | Sestrin-GATOR2相互座用のモジュレーターおよびその使用 |
WO2018197893A1 (en) | 2017-04-27 | 2018-11-01 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
JP7301757B2 (ja) | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
CA3070621A1 (en) | 2017-07-28 | 2019-01-31 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
US20200283482A1 (en) | 2017-08-14 | 2020-09-10 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
EP4306524A2 (en) | 2017-08-29 | 2024-01-17 | PureTech LYT, Inc. | Lymphatic system-directing lipid prodrugs |
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
AU2018338314A1 (en) | 2017-09-22 | 2020-04-09 | Kymera Therapeutics, Inc | Protein degraders and uses thereof |
KR20200073216A (ko) | 2017-10-19 | 2020-06-23 | 바이엘 애니멀 헬스 게엠베하 | 동물에서의 질환의 치료 및 방지를 위한 융합된 헤테로방향족 피롤리돈의 용도 |
US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
EP3727362A4 (en) | 2017-12-19 | 2021-10-06 | PureTech LYT, Inc. | MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
IL275649B2 (en) | 2017-12-26 | 2023-12-01 | Kymera Therapeutics Inc | IRAK joints and used in them |
EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND THEIR USES |
EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
AU2019212969A1 (en) | 2018-01-29 | 2020-08-13 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
SG11202006701TA (en) | 2018-01-29 | 2020-08-28 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
IL276437B2 (en) | 2018-02-13 | 2024-03-01 | Bayer Ag | Use of 5-fluoro-4-(4-fluoro-2-methoxyphenyl)-N-{4-[(S-methylsulfonimidoyl)methyl]pyridin-2-yl}pyridin-2-amine for the treatment of diffuse large B-cell lymphoma |
CN117304157A (zh) | 2018-02-27 | 2023-12-29 | 阿塔克斯生物制药有限公司 | 作为tcr-nck相互作用的抑制剂的色烯衍生物 |
CA3093130C (en) | 2018-04-19 | 2023-10-17 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
JP2021522237A (ja) | 2018-04-24 | 2021-08-30 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | プテリジノン化合物およびその使用 |
HRP20220710T1 (hr) | 2018-04-24 | 2022-07-22 | Merck Patent Gmbh | Antiproliferacijski spojevi i njihova uporaba |
EP3788047A2 (en) | 2018-05-04 | 2021-03-10 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
MX2020011639A (es) | 2018-05-04 | 2021-02-15 | Incyte Corp | Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr). |
PL3793565T3 (pl) | 2018-05-14 | 2022-05-02 | Gilead Sciences, Inc. | Inhibitory MCL-1 |
JP2021525795A (ja) * | 2018-05-25 | 2021-09-27 | カルトス セラピューティクス,インコーポレイテッド | 骨髄増殖性腫瘍を治療する方法 |
EP3813946A4 (en) | 2018-06-15 | 2022-06-01 | Anakuria Therapeutics, Inc. | RAPAMYCIN ANALOGS AND THEIR USES |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
CN108707119A (zh) * | 2018-06-25 | 2018-10-26 | 抚顺大恒化工有限公司 | 一种Momelotinib的制备方法 |
EP3817748A4 (en) | 2018-07-06 | 2022-08-24 | Kymera Therapeutics, Inc. | TRICYCLIC CRBN LIGANDS AND USES THEREOF |
AU2019301811B2 (en) | 2018-07-13 | 2022-05-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
WO2020051424A1 (en) | 2018-09-07 | 2020-03-12 | Pic Therapeutics | Eif4e inhibitors and uses thereof |
CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
WO2020086556A1 (en) | 2018-10-24 | 2020-04-30 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | POLYMORPHIC COMPOUNDS AND USES THEREOF |
SG11202103484RA (en) | 2018-10-30 | 2021-05-28 | Gilead Sciences Inc | Quinoline derivatives as alpha4beta7 integrin inhibitors |
CN112969504B (zh) | 2018-10-30 | 2024-04-09 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
AU2019373244B2 (en) | 2018-10-30 | 2022-05-26 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
CN112996786A (zh) | 2018-10-30 | 2021-06-18 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
CN113348021A (zh) | 2019-01-23 | 2021-09-03 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
KR20210134738A (ko) | 2019-03-14 | 2021-11-10 | 상하이 시너지 파마슈티컬 사이언시스 코., 엘티디. | Jak 억제제 및 그 제조방법과 의약분야에서의 응용 |
CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2020201753A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
EP3946360A4 (en) | 2019-04-05 | 2023-05-10 | Kymera Therapeutics, Inc. | STAT DEGRADING AGENTS AND THEIR USES |
EP3976192A1 (en) | 2019-05-31 | 2022-04-06 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2021091535A1 (en) | 2019-11-05 | 2021-05-14 | Constellation Pharmaceuticals, Inc. | Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor |
WO2020256739A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
WO2020257644A1 (en) | 2019-06-21 | 2020-12-24 | Constellation Pharmaceuticals, Inc. | Methods of treating myeloproliferative disorders |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CN110330484B (zh) * | 2019-07-18 | 2022-08-26 | 中国药科大学 | 取代类苯基嘧啶衍生物作为jak激酶抑制剂或其可药用的盐、制备方法及用途 |
KR20220047323A (ko) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
AU2020345962A1 (en) | 2019-09-11 | 2022-03-31 | Vincere Biosciences, Inc. | USP30 inhibitors and uses thereof |
BR112022004451A2 (pt) | 2019-09-13 | 2022-06-21 | Nimbus Saturn Inc | Antagonistas de hpk1 e usos dos mesmos |
BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
IL292612A (en) | 2019-11-01 | 2022-07-01 | Navitor Pharm Inc | Treatment methods using mtorc1 modulator |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
US11897891B2 (en) | 2019-12-04 | 2024-02-13 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
EP4069223A4 (en) | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
EP4079730A4 (en) * | 2019-12-16 | 2023-11-29 | Oncobix Co., Ltd. | NOVEL DEUTERIUM SUBSTITUTED PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME |
WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス, インコーポレイテッド | Irak分解剤およびそれらの使用 |
KR20220151160A (ko) | 2019-12-23 | 2022-11-14 | 카이메라 쎄라퓨틱스 인코포레이티드 | Smarca 분해제 및 이의 용도 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
WO2021178488A1 (en) | 2020-03-03 | 2021-09-10 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
CN113583020B (zh) * | 2020-04-30 | 2022-04-22 | 百极弘烨(广东)医药科技有限公司 | 一种jak2抑制剂及应用 |
BR112022021963A2 (pt) | 2020-04-30 | 2022-12-13 | Gilead Sciences Inc | Inibidores macrocíclicos de peptidilarginina desiminases |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
CA3186504A1 (en) | 2020-08-17 | 2022-02-24 | Stephen J. Blakemore | Bicycle conjugates specific for nectin-4 and uses thereof |
CN112142675B (zh) * | 2020-10-09 | 2021-11-30 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
CN117015531A (zh) | 2020-12-02 | 2023-11-07 | 医肯纳肿瘤学公司 | Tead抑制剂及其用途 |
TW202241884A (zh) | 2020-12-22 | 2022-11-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
WO2022140326A1 (en) | 2020-12-22 | 2022-06-30 | Gilead Sciences, Inc. | Substituted indole compounds |
TW202233174A (zh) | 2020-12-22 | 2022-09-01 | 美商基利科學股份有限公司 | 肽基精胺酸去亞胺酶之抑制劑 |
WO2022167457A1 (en) | 2021-02-02 | 2022-08-11 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
BR112023015584A2 (pt) | 2021-02-02 | 2023-10-24 | Liminal Biosciences Ltd | Antagonistas de gpr84 e usos dos mesmos |
WO2022166916A1 (zh) * | 2021-02-05 | 2022-08-11 | 深圳市塔吉瑞生物医药有限公司 | 取代的杂芳基衍生物及其组合物及用途 |
TW202246283A (zh) | 2021-02-09 | 2022-12-01 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
IL304905A (en) | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | IRAK4 joints and their uses |
EP4301756A1 (en) | 2021-03-05 | 2024-01-10 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
WO2022221642A1 (en) | 2021-04-16 | 2022-10-20 | Gilead Sciences, Inc. | Thienopyrrole compounds |
CA3215081A1 (en) | 2021-04-16 | 2022-10-20 | Alfredo C. Castro | Mek inhibitors and uses thereof |
EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CN117794546A (zh) | 2021-08-10 | 2024-03-29 | 葛兰素史密斯克莱有限责任公司 | 莫洛替尼组合疗法 |
WO2023023473A1 (en) | 2021-08-16 | 2023-02-23 | Sierra Oncology, Inc. | Methods of using momelotinib to treat chronic kidney disease |
WO2023028238A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
TW202315621A (zh) | 2021-08-25 | 2023-04-16 | 美商皮克醫療公司 | Eif4e抑制劑及其用途 |
CA3230800A1 (en) | 2021-09-10 | 2023-03-16 | Gilead Sciences, Inc. | Thienopyrrole compounds |
WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
WO2023152773A1 (en) * | 2022-02-14 | 2023-08-17 | Dr. Reddy's Institute Of Life Sciences | Solid forms of momelotinib salts and improved processes for the preparation of momelotinib |
WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
CN117304179A (zh) * | 2022-06-21 | 2023-12-29 | 苏州泽璟生物制药股份有限公司 | 杰克替尼二盐酸盐一水合物的制备工艺 |
WO2024028364A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
WO2024028363A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
WO2024035771A2 (en) * | 2022-08-09 | 2024-02-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Ulk3 inhibitors and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3481932A (en) * | 1967-09-01 | 1969-12-02 | Searle & Co | 2-anilino-5-methyl-6-phenylpyrimidines and congeners |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
EP1210099A4 (en) * | 1999-08-13 | 2006-01-18 | Scripps Research Inst | TECHNIQUES AND COMPOSITIONS SUITABLE FOR THE MODULATION OF ANGIOGENESIS BASED ON RAF PROTEINKINASE AND KINASE RAS |
GB9924862D0 (en) * | 1999-10-20 | 1999-12-22 | Celltech Therapeutics Ltd | Chemical compounds |
US7122544B2 (en) * | 2000-12-06 | 2006-10-17 | Signal Pharmaceuticals, Llc | Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto |
CA2436487A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd. | Methods of inhibiting kinases |
ES2292753T4 (es) | 2001-03-29 | 2009-02-16 | Vertex Pharmaceuticals Incorporated | Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas. |
US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
NZ532243A (en) | 2001-09-12 | 2006-03-31 | Virexx Medical Corp | Vascular occlusion solid-phase agent with immobilised platelet binding agent |
DE60317198T2 (de) | 2002-05-23 | 2008-12-04 | Cytopia Research Pty. Ltd., Richmond | Proteinkinaseinhibitoren |
US7304071B2 (en) | 2002-08-14 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
DE60330895D1 (de) * | 2002-11-01 | 2010-02-25 | Vertex Pharma | Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen |
JP4688498B2 (ja) | 2002-11-04 | 2011-05-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakインヒビターとしてのヘテロアリール−ピリミジン誘導体 |
JP2006508107A (ja) * | 2002-11-05 | 2006-03-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | Jakおよび他のプロテインキナーゼのインヒビターとして有用な化合物 |
GB0317841D0 (en) * | 2003-07-30 | 2003-09-03 | Cyclacel Ltd | Compound |
CA2533474A1 (en) * | 2003-07-30 | 2005-02-10 | Shudong Wang | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
TW200626559A (en) * | 2004-10-13 | 2006-08-01 | Wyeth Corp | Anilino-pyrimidine analogs |
US7593820B2 (en) | 2005-05-12 | 2009-09-22 | Cytopia Research Pty Ltd | Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof |
JP2008543775A (ja) * | 2005-06-08 | 2008-12-04 | ターゲジェン インコーポレーティッド | 眼の障害を治療するための方法および組成物 |
EP1979329A2 (en) * | 2006-01-30 | 2008-10-15 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use |
WO2007101232A2 (en) | 2006-02-28 | 2007-09-07 | Cytopia Research Pty, Ltd. | Inhibition of jak2 as a treatment of pulmonary arterial hypertension |
FR2911139A1 (fr) * | 2007-01-05 | 2008-07-11 | Sanofi Aventis Sa | Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk |
PL2152701T3 (pl) * | 2007-03-12 | 2016-10-31 | Związki fenyloaminopirymidyny i ich zastosowania | |
US8530480B2 (en) * | 2007-09-04 | 2013-09-10 | The Scripps Research Institute | Substituted pyrimidinyl-amines as protein kinase inhibitors |
WO2009029998A1 (en) | 2007-09-06 | 2009-03-12 | Cytopia Research Pty Ltd | Retrometabolic compounds |
US20100310563A1 (en) | 2007-11-30 | 2010-12-09 | Bumm Thomas G P | Methods for treating induced cellular proliferative disorders |
CN102112131A (zh) | 2008-08-05 | 2011-06-29 | 塔格根公司 | 治疗地中海贫血的方法 |
MX2013006261A (es) | 2010-12-03 | 2013-10-01 | Ym Biosciences Australia Pty | Tratamiento de condiciones mediadas por jak2. |
MX2013012785A (es) | 2011-05-02 | 2014-05-28 | Ym Biosciences Australia Pty | Tratamiento del mieloma multiple. |
US8809359B2 (en) | 2012-06-29 | 2014-08-19 | Ym Biosciences Australia Pty Ltd | Phenyl amino pyrimidine bicyclic compounds and uses thereof |
-
2008
- 2008-03-12 PL PL08714386.3T patent/PL2152701T3/pl unknown
- 2008-03-12 AU AU2008226327A patent/AU2008226327B2/en active Active
- 2008-03-12 RS RS20160040A patent/RS54533B1/en unknown
- 2008-03-12 BR BR122020010759-6A patent/BR122020010759B1/pt active IP Right Grant
- 2008-03-12 WO PCT/AU2008/000339 patent/WO2008109943A1/en active Application Filing
- 2008-03-12 MX MX2009009792A patent/MX2009009792A/es active IP Right Grant
- 2008-03-12 US US12/530,610 patent/US8486941B2/en active Active
- 2008-03-12 CN CN200880015782.9A patent/CN101861313B/zh active Active
- 2008-03-12 BR BRPI0808888A patent/BRPI0808888B8/pt active IP Right Grant
- 2008-03-12 SI SI200831536T patent/SI2152701T1/sl unknown
- 2008-03-12 PT PT87143863T patent/PT2152701E/pt unknown
- 2008-03-12 CN CN201410208369.1A patent/CN104030990B/zh active Active
- 2008-03-12 JP JP2009552972A patent/JP2010520892A/ja not_active Withdrawn
- 2008-03-12 HU HUE08714386A patent/HUE029188T2/en unknown
- 2008-03-12 EP EP15182427.3A patent/EP3023422A1/en not_active Withdrawn
- 2008-03-12 RU RU2009137363/04A patent/RU2498983C2/ru active
- 2008-03-12 EP EP08714386.3A patent/EP2152701B1/en active Active
- 2008-03-12 DK DK08714386.3T patent/DK2152701T3/en active
- 2008-03-12 KR KR1020097021274A patent/KR101566840B1/ko active IP Right Grant
- 2008-03-12 CA CA2702650A patent/CA2702650C/en active Active
- 2008-03-12 KR KR1020157009274A patent/KR20150043565A/ko active Search and Examination
- 2008-03-12 ES ES08714386.3T patent/ES2557930T3/es active Active
- 2008-03-12 KR KR1020167024491A patent/KR101737753B1/ko active IP Right Grant
-
2009
- 2009-10-12 ZA ZA2009/06848A patent/ZA200906848B/en unknown
-
2011
- 2011-04-13 HK HK11103752.9A patent/HK1149749A1/xx unknown
-
2013
- 2013-06-07 US US13/913,362 patent/US9238628B2/en active Active
- 2013-06-07 US US13/913,369 patent/US9233934B2/en active Active
- 2013-09-06 JP JP2013184807A patent/JP2013249316A/ja active Pending
-
2014
- 2014-02-03 JP JP2014018467A patent/JP5746388B2/ja active Active
-
2015
- 2015-03-13 JP JP2015050435A patent/JP5940700B2/ja active Active
- 2015-12-07 US US14/960,710 patent/US20210309615A1/en not_active Abandoned
- 2015-12-16 HR HRP20151386TT patent/HRP20151386T1/hr unknown
-
2016
- 2016-02-09 CY CY20161100104T patent/CY1117180T1/el unknown
- 2016-05-16 JP JP2016097703A patent/JP2016175934A/ja active Pending
-
2022
- 2022-04-20 US US17/724,825 patent/US20220388967A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1149749A1 (en) | Phenyl amino pyrimidine compounds and uses thereof | |
IL244442B (en) | Compounds of converted acylanilides and their use | |
PT2114900T (pt) | Compostos à base de tiopirimidina e as suas utilizações | |
IL196313A0 (en) | Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents | |
EP2152079A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
ZA201308294B (en) | Heterocyclic compounds and their uses | |
EP2295425A4 (en) | 1-SUBSTITUTED PYRIDYL-PYRAZOLYLAMIDE COMPOUNDS AND THEIR USE | |
EP2184285A4 (en) | Heterocyclic compound and its use | |
EP2151440A4 (en) | Heterocyclic compound and its use | |
ZA200904857B (en) | Quinoxaline compounds and use thereof | |
EP2181987A4 (en) | HETEROCYCLIC COMPOUND AND USE THEREOF | |
GB0621160D0 (en) | Compounds and uses thereof | |
EP2143709A4 (en) | AMIDE COMPOUND AND USE THEREOF | |
EP2151431A4 (en) | AMIDE COMPOUND AND USE THEREOF | |
EP2124908A4 (en) | CONNECTIONS AND ITS USE | |
EP2120563A4 (en) | CONNECTIONS AND ITS USES | |
IL202496A0 (en) | Compounds and uses thereof 849 | |
EP2170874A4 (en) | NEW COMPOUNDS AND THEIR USE | |
GB0718718D0 (en) | Compound and use thereof | |
IL192820A0 (en) | Novel compounds and use thereof | |
HK1223619A1 (zh) | 苯基氨基嘧啶化合物及其用途 | |
GB0708445D0 (en) | Compounds and uses thereof | |
EP2099459A4 (en) | COMPOUNDS AND USES THEREOF | |
ME02378B (me) | Fenil aminopirimidinska jedinjenja i njihova primena | |
EP2120957A4 (en) | COMPOUNDS AND USES THEREOF |